Neurizon to present Q1 FY2026 Results
Filed with ASX · · 24 pages · English
31 October 2025 – Melbourne Australia: Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA) (“Neurizon” or “the Company”), a clinical-stage biotech company advancing treatments for neurodegenerative diseases, is pleased to announce an upcoming webinar presentation to provide shareholders with an update on the Company’s Q1 FY2026 results and recent progress in advancing NUZ-001 toward participation in
Neurizon Therapeutics Limited on 6ix
Story so far
Earlier from Neurizon Therapeutics
- Australian Patent Granted for NUZ-001
- FDA Lifts Clinical Hold on NUZ-001
- Neurizon Raises $5m via Institutional Placement
- R&D Tax Incentive Advance & Overseas Finding Approval
- Appendix 4E and 2025 Annual Report
Later from Neurizon Therapeutics
- Elanco executive appointed as Neurizon's Board Observer
- Neurizon Completes GMP Tablet Registration Batches
- FDA Clears NUZ-001 for Entry into HEALEY ALS Platform Trial
- Trading Halt
- Equity Raising Presentation
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics